Resveratrol derivatives: an updated patent review (2012-2015)

References

• Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discovery. 2006;5:493–506.
   PubMed Web of Science ®Google Scholar
• Takaoka M. Resveratrol, a new phenolic compound, from Veratrum grandiflorum. J Chem Soc Japan. 1939;60:1090–1100.
   Google Scholar
• Siemann EH, Creasy LL. Concentration of the phytoalexin resveratrol in wine. Am J Eno Vitic. 1992;43:49–52.
   Web of Science ®Google Scholar
• Cottart C-H, Nivet-Antoine V, Beaudeux J-L. Review of recent data on the metabolism, biological effects, and toxicity of resveratrol in humans. Mol Nutr Food Res. 2014;58:7–21.
   PubMed Web of Science ®Google Scholar
• Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997;275:218–220.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Adhami VM, Afaq F, et al. Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res. 2001;7:1466–1473.
   PubMed Web of Science ®Google Scholar
• Delmas D, Solary E, Latruffe N. Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem. 2011;18:1100–1121.
   PubMed Web of Science ®Google Scholar
• Cai H, Scott E, Kholghi A, et al. Cancer chemoprevention: evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci Transl Med. 2015;298:298ra117.
   Web of Science ®Google Scholar
• Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003;425:191–196.
   PubMed Web of Science ®Google Scholar
• Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem. 2010;285:8340–8351.
   PubMed Web of Science ®Google Scholar
• Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 2012;148:421–433.
   PubMed Web of Science ®Google Scholar
• Walle T, Hsieh F, De Legge M, et al. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004;32:1377–1382.
   PubMed Web of Science ®Google Scholar
• Shen T, Wang X-N, Lou H-X. Natural stilbenes: an overview. Nat Prod Rep. 2009;26:916–935.
   PubMed Web of Science ®Google Scholar
• Rivière C, Pawlus AD, Mérillon J-M. Natural stilbenoids: distribution in the plant kingdom and chemotaxonomic interest in vitaceae. Nat Prod Rep. 2012;29:1317–1333.
   PubMed Web of Science ®Google Scholar
• Snyder SA, ElSohly AM, Kontes F. Synthetic approaches to oligomeric natural products. Nat Prod Rep. 2011;28:897–924.
   PubMed Web of Science ®Google Scholar
• Keylor MH, Matsuura BS, Stephenson CRJ. Chemistry and biology of resveratrol-derived natural products. Chem Rev. 2015;115:8976–9027.
   PubMed Web of Science ®Google Scholar
• Pettit GR, Singh SB, Boyd MR, et al. Antineoplastic agents 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6. J Med Chem. 1995;38:1666–1672.
   PubMed Web of Science ®Google Scholar
• Cirla A, Mann J. Combretastatins: from natural products to drug discovery. Nat Prod Rep. 2003;20:558–564.
   PubMed Web of Science ®Google Scholar
• Paul S, DeCastro AJ, Lee HJ, et al. Dietary intake of pterostilbene, a constituent of blueberries, inhibits the β-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. Carcinogenesis. 2010;31:1272–1278.
   PubMed Web of Science ®Google Scholar
• Su D, Cheng Y, Liu M, et al. Comparision of piceid and resveratrol in antioxidation and antiproliferation activities in vitro. PLoS ONE. 2013;8:e54505.
   PubMed Web of Science ®Google Scholar
• Li C, Lu J, Xu X, et al. pH-switched HRP-catalyzed dimerization of resveratrol: a selective biomimetic synthesis. Green Chem. 2012;14:3281–3284.
   Web of Science ®Google Scholar
• Li C, Xu X, Tao Z, et al. Resveratrol dimers, nutritional components in grape wine, are selective ROS scavengers and weak Nrf2 activators. Food Chem. 2015;173:218–223.
   PubMed Web of Science ®Google Scholar
• González-Sarrías A, Gromek S, Niesen D, et al. Resveratrol oligomers isolated from Carex species inhibit growth of human colon tumorigenic cells mediated by cell cycle arrest. J Agric Food Chem. 2011;59:8632–8638.
   PubMed Web of Science ®Google Scholar
• Pezzuto JM, Kondratyuk TP, Ogas T. Resveratrol derivatives: a patent review (2009–2012). Expert Opin Ther Patents. 2013;23:1529–1546.
   PubMed Web of Science ®Google Scholar
• Hsieh T, Huang Y, Wu JM. Control of prostate cell growth, DNA damage and repair and gene expression by resveratrol analogues, in vitro. Carcinogenesis. 2011;32:93–101.
   PubMed Web of Science ®Google Scholar
• Lei X, Yu L, Yao X, et al. New resveratrol derivatives containing trifluoromethyl groups including E-3,5-dimethoxy-2ʹ-dimethyl-diphenyl ethylene, and E-3,5-dihydroxy-2ʹ-dimethyl-diphenyl ethylene, useful for adjusting immune response and protecting liver. CN103965027-A. 2014.
   Google Scholar
• Mattarei A, Biasutto L, Zoratti M, et al. New resveratrol derivatives useful to treat e.g. inflammatory conditions, viral infections, metabolic disease and cancer, as e.g. food supplement, and to prevent and/or treat e.g. muscle weakness, loss of mental acuity and memory decline. EP2774915-A1; IT1416513-B. 2014.
   Google Scholar
• Lu Y, Hong T, Yu B, et al. New resveratrol derivative used in preparing anticancer drugs for treating cancer, e.g. lung cancer, lung adenocarcinoma, liver cancer, and uterus cancer. CN102126993-A. 2011.
   Google Scholar
• Niu J, Niu Q. New resveratrol ether derivative used for preparing medicine for treating or preventing disease of T-cell proliferation associated with or mediated by proinflammatory cytokine, e.g. liver disease. CN102675061-A. 2012.
   Google Scholar
• Li W, Zhong B, He X, et al. New resveratrol derivatives useful in preparing medicine e.g. for reducing blood viscosity, inhibiting platelet coagulation, relaxing blood vessel, and treating and/or preventing cardiovascular diseases (preferably hyperlipidemia). CN102040517-A; CN102040517-B. 2015.
   Google Scholar
• Li W, Zhong B, He X, et al. New resveratrol derivative for medicine composition used in treating and/or preventing cardio-cerebrovascular disease, e.g. hyperlipidemia. CN102040516-A; CN102040516-B. 2014.
   Google Scholar
• Czarnota A, Qu L, Mohammadi F, et al. Anhydrous cosmetic compositions containing resveratrol derivatives. US08344024. 2013.
   Google Scholar
• Declercq L, Corstjens H, Maes D, et al. Topical compositions containing phosphorylated polyphenols. US08465973. 2013.
   Google Scholar
• Okamoto K, Haza Y, Kishi A, et al. New resveratrol derivative or its salt used in foodstuff, pharmaceutical or quasi-drug as anticancer (oral cavity cancer cells) agent. JP2014028772-A. 2014.
   Google Scholar
• Huang L, Yan J, Li X, et al. New resveratrol derivative used in preparing medicine for treating Alzheimer’s disease. CN103709050-A. 2014.
   Google Scholar
• Zhang F, Han Y, Bo H, et al. New polyethylene glycol modified derivative or methoxy polyethylene glycol modified derivative useful as chemical modifier for preparing water-soluble resveratrol prodrug. CN101870769-A; CN101870769-B. 2012.
   Google Scholar
• Chen J, Le Y, Liu M, et al. New resveratrol polymer complex is prepared by reacting resveratrol with chloride salt in reactor in presence of catalyst in an inert gas in organic solvent to obtain resveratrol derivative that is further reacted with water soluble polymer. CN104524595-A. 2015.
   Google Scholar
• Wang X, Yao J, Zhou J. Natural P-glycoprotein inhibitor based oral administration absorption enhancer used for pharmaceutically active molecule, preferably taxanes or camptothecin and used as carrier, includes carboxyl group containing chitosan derivative. CN104225612-A. 2014.
   Google Scholar
• An S. New resveratrol derivative useful for e.g. promoting weight loss by improving fat tissue energy metabolism, free fatty acids, triglyceride, and low-density lipoprotein cholesterol metabolism, and reducing hyperinsulinemia. CN104147026-A. 2014.
   Google Scholar
• An S. Use of resveratrol derivative for decreasing blood fat, and reducing serum triglycerides, total cholesterol and low-density lipoprotein cholesterol levels. CN104147024-A. 2014.
   Google Scholar
• Galati G, Sabzevari O, Wilson JX, et al. Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics. Toxicology. 2002;177:91–104.
   PubMed Web of Science ®Google Scholar
• Saleh T, Rajagopal D, Khan B, et al. New lipoic acid-resveratrol conjugate derivatives useful for treating or preventing a disease, disorder, or condition related to oxidative stress e.g. stroke, ischemia, reperfusion injury, renal failure, and myocardial infarction. WO2015095968-A1. 2015.
   Google Scholar
• Okamoto K, Kishi A, Matsukawa Y, et al. Preparing extract using plant of Brassicaceae, useful as functional food for preventing life-style related disease, preferably obesity involves reacting resveratrol derivative with sinapinic acid. JP2015007016-A. 2015.
   Google Scholar
• Bitzer J, Kueper T, Wabnitz P. Use of carboxylated Stilbene derivative, in topical application on skin for preventing and treating skin aging and diabetic skin. EP2801347-A1; US2014336136-A1. 2014.
   Google Scholar
• Deng S, Guan Q, Li X, et al. New resveratrol phenyl acrylamide derivatives used for treating cancer, cardiovascular disease, pathogenic microorganism infection, senile dementia and senile degenerative disease. CN102617391-A; CN102617391-B. 2013.
   Google Scholar
• Doi S, Kishi A, Matsukawa Y, et al. New adiponectin production promoter, comprises one or more types of compounds selected from a resveratrol derivative, or its pharmacologically acceptable salt, useful for improving production of adiponectin. JP2013010721-A. 2013.
   Google Scholar
• Cai J, Yang P, Yao S. New resveratrol germanium sesquioxide compound e.g. used in preparing antitumor medicine, prepared by subjecting germanium and double bond of material having resveratrol structure to addition reaction, and hydrolyzing. CN102558222-A; CN102558222-B. 2014.
   Google Scholar
• Kishi A, Doi S, Matsukawa T, et al. New resveratrol polymerized derivative useful as e.g. anticancer agent, anticancer agent for oral cancer, and therapeutic agent in food, pharmaceutical, quasi-drug and cosmetic for treating dermatological disorder. WO2013061455-A1; US2014288334-A1; US9051245-B2. 2014.
   Google Scholar
• Doi S, Kishi A, Matsukawa Y, et al. Metabolism promoter useful for preventing and/or improving metabolic syndrome e.g. arteriosclerosis and food, pharmaceutical composition, and quasi-drug, comprises resveratrol derivative and salt. JP2014070052-A. 2014.
   Google Scholar
• Doi S, Kishi A, Matsukawa Y, et al. Metabolism promoter composition used for accelerating metabolism of fat tissue, regulating circadian rhythm, and treating metabolic syndrome, comprises resveratrol derivatives as active ingredients. JP2014070053-A. 2014.
   Google Scholar
• Doi S, Kishi A, Matsukawa Y, et al. Peroxisome proliferator-activated receptor-gamma coactivator-1 alpha expression promoter used as antiobesity agent and used for preventing and treating metabolic syndrome, comprises resveratrol or its derivative. JP2014028776-A. 2014.
   Google Scholar
• Doi S, Kishi A, Matsukawa Y, et al. Agent useful for treating life style related disease, including diabetes, preferably type-2 diabetes and hypoglycemia, preferably postprandial hyperglycemia, comprises resveratrol derivative. JP2013136547-A. 2013.
   Google Scholar
• Doi S, Kishi A, Matsukawa Y, et al. gent useful for inhibiting fat cell hypertrophy, preventing and/or treating obesity and preventing metabolic syndrome, and in e.g. pharmaceutical composition, comprises one or more compounds including resveratrol derivative. JP2013095693-A. 2013.
   Google Scholar
• Doi S, Kishi A, Matsukawa Y, et al. Sirutin activity promoting agent useful for preventing aging, obesity, fatty liver, diabetes and myocardial inflammation, comprises resveratrol derivatives. JP2012246242-A; JP5772220-B2. 2012.
   Google Scholar
• Chen Y, Hu F, Gao Y, et al. Design, synthesis, and evaluation of methoxylated resveratrol derivatives as potential antitumor agents. Res Chem Intermed. 2015;41:2725–2738.
   Web of Science ®Google Scholar
• Jin L, Ren Y-J, Du C. Synthesis and antitumor activities of resveratrol derivatives on cervical cancer HeLa cells. Chem Nat Compd. 2015;51:652–655.
   Web of Science ®Google Scholar
• Pang X, Yang X, Zhai G. Polymer-drug conjugates: recent progress on administration routes. Expert Opin on Drug Delivery. 2014;11:1075–1086.
   PubMed Web of Science ®Google Scholar
• Dosio F, Stella B, Arpicco S, et al. Macromolecules as taxane delivery systems. Expert Opin on Drug Delivery. 2011;8:33–55.
   PubMed Web of Science ®Google Scholar
• Varshosaz J. Dextran conjugates in drug delivery. Expert Opin on Drug Delivery. 2012;9:509–523.
   PubMed Web of Science ®Google Scholar
• Mattarei A, Carraro M, Azzolini M, et al. New water-soluble carbamate ester derivatives of resveratrol. Molecules. 2014;19:15900–15917.
   PubMed Web of Science ®Google Scholar
• Mattarei A, Azzolini M, Zoratti M, et al. N-Monosubstituted methoxy-oligo(ethylene glycol) carbamate ester prodrugs of resveratrol. Molecules. 2015;20:16085–16012.
   PubMed Web of Science ®Google Scholar
• Jiang L-Y, He S, Jiang K-Z, et al. Resveratrol and its oligomers from wine grapes are selective 1O2 quenchers: mechanistic implication by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry and theoretical calculation. J Agric Food Chem. 2010;58:9020–9027.
   PubMed Web of Science ®Google Scholar
• Saleh MC, Connell BJ, Rajagopal D, et al. Co-administration of resveratrol and lipoic acid, or their synthetic combination, enhances neuroprotection in a rat model of ischemia/reperfusion. Plos ONE. 2014;9:e87865.
   PubMed Web of Science ®Google Scholar
• Sassi N, Mattarei A, Azzolini M, et al. Cytotoxicity of mitochondria-targeted resveratrol derivatives: interactions with respiratory chain complexes and ATP synthase. Biochim Biophys Acta. 2014;1837:1781–1789.
   PubMed Web of Science ®Google Scholar
• Ruan B-F, Cheng H-J, Ren J, et al. Novel 2H-chromen-2-one derivatives of resveratrol: design, synthesis, modeling and use as human monoamine oxidase inhibitors. Eur J Med Chem. 2015;103:185–190.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Fu J, Shurlknight KL, et al. Novel resveratrol-based aspirin prodrugs: synthesis, metabolism, and anticancer activity. J Med Chem. 2015;58:6494–6506.
   PubMed Web of Science ®Google Scholar
• Antus C, Radnai B, Dombovari P, et al. Anti-inflammatory effects of a triple-bond resveratrol analog: structure and function relationship. Eur J Pharmcol. 2015;748:61–67.
   PubMed Web of Science ®Google Scholar
• Tanini D, Panzella L, Amorati R, et al. Resveratrol-based benzoselenophenes with an enhanced antioxidant and chain breaking capacity. Org Biomol Chem. 2015;13:5757–5764.
   PubMed Web of Science ®Google Scholar
• Jiang F, Xie D, Fu L, et al. New resveratrol dimer derivatives e.g. (E)-3-(3,5-dimethoxylphenyl)-2-(4-methoxyphenyl)-5-(3,4,5-trimethoxystyryl)benzofuran useful for inhibiting growth of e.g. human breast cancer MCF-7 cells and human cervical cancer HeLa cells. CN103214441-A; CN103214441-B. 2014.
   Google Scholar
• Lu J, Li C, Chai Y-F, et al. The antioxidant effect of imine resveratrol analogues. Bioorg Med Chem Lett. 2012;22:5744–5747.
   PubMed Web of Science ®Google Scholar
• Li C, Xu X, Wang XJ, et al. Imine resveratrol analogues: molecular design, Nrf2 activation and SAR analysis. PLoS ONE. 2014;9:e101455.
   PubMed Web of Science ®Google Scholar
• Hupfeld J, Efferth T. Drug resistance of human immunodeficiency virus and overcoming it by natural products. Vivo. 2009;23:1–6.
   PubMed Web of Science ®Google Scholar